Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2511070 | 0.94 | CXCR4 (1.00) | CXCR4 | |
| SCHEMBL2509892 | 0.94 | CXCR4 (0.89) | CXCR4 | |
| SCHEMBL2511350 | 0.93 | CXCR4 (0.86) | CXCR4 | |
| SCHEMBL15703429 | 0.93 | CXCR4 (0.86) | CXCR4 | |
| SCHEMBL2507407 | 0.92 | CXCR4 (0.86) | CXCR4 | |
| SCHEMBL2510514 | 0.92 | CXCR4 (0.88) | CXCR4 | |
| SCHEMBL15703631 | 0.92 | CXCR4 (0.85) | CXCR4 | |
| SCHEMBL2509004 | 0.92 | CXCR4 (0.85) | CXCR4 | |
| SCHEMBL2508321 | 0.92 | CXCR4 (1.00) | CXCR4 | |
| SCHEMBL2511147 | 0.92 | CXCR4 (0.85) | CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1752455-B1 | Chemokine receptor binding heterocyclic compounds | ANORMED INC (CA) | 2010-11-10 | — | — | EP | claimed |
| US-20100035941-A1 | METHODS FOR INCREASING BLOOD FLOW AND/OR PROMOTING TISSUE REGENERATION | GENZYME CORPORATION | 2010-02-11 | — | — | US | claimed |
| US-20060252795-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2006-11-09 | — | — | US | claimed |
| US-6734191-B2 | PREFERABLY TERTIARY AMINES COMPRISING TETRAHYDROQUINOLINE AND BENZIMIDAZOLE; USE TREATING HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND FELINE IMMUNODEFICIENCY VIRUS (FIV) | ANORMED, INC. (CA) | 2004-05-11 | — | — | US | claimed |
| US-20190175549-A1 | CXCR4 RECEPTOR-BINDING COMPOUNDS USEFUL FOR INCREASING INTERFERON LEVEL | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-06-13 | — | — | US | disclosed |
| US-20190175557-A1 | COMPOUNDS USEFUL FOR DECREASING INTERFERON LEVEL | UNIVERSITÉ PARIS CITÉ (FR) | 2019-06-13 | — | — | US | disclosed |
| WO-2017216373-A1 | CXCR4 RECEPTOR-BINDING COMPOUNDS USEFUL FOR INCREASING INTERFERON LEVEL | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2017-12-21 | — | — | WO | disclosed |
| WO-2017216368-A1 | COMPOUNDS USEFUL FOR DECREASING INTERFERON LEVEL | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2017-12-21 | — | — | WO | disclosed |
| EP-1991221-B1 | METHODS FOR INCREASING BLOOD FLOW AND/OR PROMOTING TISSUE REGENERATION | GENZYME CORP (US) | 2014-05-21 | — | — | EP | disclosed |
| US-20130095076-A1 | Methods For Increasing Blood Flow And/Or Promoting Tissue Regeneration | GENZYME CORPORATION (US) | 2013-04-18 | — | — | US | disclosed |
| US-20110245265-A1 | CXCR4 ANTAGONISTS FOR KIDNEY INJURY | GENZYME CORPORATION (US) | 2011-10-06 | — | — | US | disclosed |
| EP-1752455-B1 | Chemokine receptor binding heterocyclic compounds | ANORMED INC (CA) | 2010-11-10 | — | — | EP | disclosed |
| EP-1631307-A1 | METHODS TO MOBILIZE PROGENITOR/STEM CELLS | ANORMED INC. (CA) | 2006-03-08 | — | — | EP | disclosed |
| US-20050043367-A1 | Methods to mobilize progenitor/stem cells | ANORMED CORPORATION (CA) | 2005-02-24 | — | — | US | disclosed |
| WO-2005000333-A1 | METHODS TO MOBILIZE PROGENITOR/STEM CELLS | ANORMED INC. (CA) | 2005-01-06 | — | — | WO | disclosed |
| US-20040171638-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2004-09-02 | — | — | US | disclosed |
| US-6734191-B2 | PREFERABLY TERTIARY AMINES COMPRISING TETRAHYDROQUINOLINE AND BENZIMIDAZOLE; USE TREATING HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND FELINE IMMUNODEFICIENCY VIRUS (FIV) | ANORMED, INC. (CA) | 2004-05-11 | — | — | US | disclosed |
| EP-1317451-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2003-06-11 | — | — | EP | disclosed |
| US-20030028022-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2003-02-06 | — | — | US | disclosed |
| WO-2002034745-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245265-A1 | CXCR4 ANTAGONISTS FOR KIDNEY INJURY | CXCR4, CXCR3, CXCR1 | CXCR4 1/4885 |
| US-20050043367-A1 | Methods to mobilize progenitor/stem cells | CXCL12, CXCR4, CXCR1 | CXCR4 2/4885 |
| US-20060252795-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR3, CCR2 | CXCR4 7/4885 |
| US-20040171638-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR3, CCR2 | CXCR4 7/4885 |
| US-20190175549-A1 | CXCR4 RECEPTOR-BINDING COMPOUNDS USEFUL FOR INCREASING INTERFERON LEVEL | CXCR4, IFNAR1, CXCR3 | CXCR4 1/4885 |
| US-20100035941-A1 | METHODS FOR INCREASING BLOOD FLOW AND/OR PROMOTING TISSUE REGENERATION | CCR2, CXCR4, CXCR2 | CXCR4 2/4885 |
| US-20130095076-A1 | Methods For Increasing Blood Flow And/Or Promoting Tissue Regeneration | CXCL12, CXCR4, CXCR1 | CXCR4 2/4885 |
| US-20030028022-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR3, CCR2 | CXCR4 7/4885 |
| US-20190175557-A1 | COMPOUNDS USEFUL FOR DECREASING INTERFERON LEVEL | IFNAR1, CXCR4, CXCR3 | CXCR4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.